Announcement PDF ASX Announcement Monday 7th April 2025 National Scale up of Public Funded HIV Self-Test Vending Machines • Initial order received for Atomo HIV Self-Tests from Thorne Harbour Health worth ~$230k, with further funding in place for expanded testing during 2026 • Atomo HIV Self-Test launched in New Zealand through Chemist Warehouse Sydney, Monday 7th April 2025 - Atomo Diagnostics is pleased to announce the national scale up of the CONNECT Programme, to provide free HIV self-tests through Vending Machines across Australia. The initiative, funded by the Federal Government in the May Budget 2024, marks a significant step forward in the use of HIV Self-Testing by public health and reflects an increasing use of at-home testing to cost effectively address public health challenges. Thorne Harbour Health (THH) have placed an order for Atomo HIV tests worth ~$230,000 to support initial scale up of the program nationally. This program represents a significant expansion of vending machine access to free HIV self-tests, a key pillar of the Federal Government’s self-test 2024 budget commitment and is in addition to and separate from the “MyTest” Vending Machine rollout now underway by the Ministry of Health NSW across the State. THH operates in South Australia as well as Victoria - CONNECT National being coordinated out of South Australia. Additionally, Atomo’s HIV Self-Test has been registered for import into New Zealand with the launch of the product commencing this week through the Chemist Warehouse, the biggest retail pharmacy chain in New Zealand. Atomo’s CEO John Kelly said, “We are excited about the growing adoption of HIV Self-Testing as critical to the government’s efforts fight against HIV and look forward to continuing to work with THH and others to ensure that tests are readily available in the community where needed.” Mr Kelly added “We are also pleased to be able to expand our supply of the Atomo HIV Self-Test into the New Zealand market and we continue to look for international markets where we can secure meaningful pharmacy retail channel access for our HIV product.” Atomo Diagnostics Limited ACN 142 925 684 Level 1, 3-5 George St Leichhardt NSW 2040 For more information, please contact: John Kelly Atomo Diagnostics john.kelly@atomodiagnostics.com Phone: +61 401 922 279 This announcement was authorised by the Managing Director & CEO. About Atomo Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo’s unique patented devices simplify testing procedures, enhance usability, and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, COVID-19, viral vs bacterial differentiation, as well as the early detection of pregnancy. See more at www.atomodiagnostics.com Atomo Diagnostics Limited ACN 142 925 684 Level 1, 3-5 George St Leichhardt NSW 2040